Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx, Squamous Cell Carcinoma
Interventions: Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Primary Ciliary Dyskinesia
Interventions: VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide J, Semaglutide B; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 55
States / cities: Gilbert, Arizona • Costa Mesa, California • La Mesa, California + 45 more

Conditions: Hypertension
Interventions: olmesartan medoxomil, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more

Conditions: Chronic Lymphocytic Leukemia, CLL, SLL, Small Lymphocytic Lymphoma
Interventions: TP-0903, TP-0903 and ibrutinib combination therapy; Drug · Combination Product
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more

Conditions: Wound Healing
Interventions: GSK1278863, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more

Conditions: Cardiovascular Diseases
Interventions: AngioDefender, Ultrasound; Device
Lead sponsor: Everist Genomics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Boulder, Colorado • Derby, Connecticut • Boston, Massachusetts + 1 more

Conditions: Addiction, Opioid
Interventions: Enhanced Monitoring and Feedback (EMF), NIATx/MAT Academy, NIATx-Internal Facilitation (NIATx-IF), NIATx-External Facilitation (NIATx-EF); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Olympia, Washington

Conditions: Spina Bifida
Interventions: Altimate Medical EasyStand Bantam; Device
Lead sponsor: University of St. Augustine for Health Sciences; Other
Eligibility: 5 Years to 12 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diastolic Dysfunction
Interventions: MITOQUINOL MESYLATE then placebo, Placebo, then MITOQUINOL MESYLATE; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Device Latency
Interventions: MIND1 System; Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions: Liraglutide Pen Injector [Saxenda], Medication Diary; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis
Interventions: LY3337641, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Palm Desert, California • Palo Alto, California • Denver, Colorado + 12 more

Conditions: Cerebrovascular Accident, Transient Ischemic Attack, ADHD
Interventions: atomoxetine, Stimulants, No intervention (general population); Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 72,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Tarzana, California • Torrance, California + 4 more

Conditions: Diabetes Mellitus, Type II
Interventions: LY2189265; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Hidradenitis Suppurativa
Interventions: SAR442970, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Ocala, Florida • Tampa, Florida + 3 more

Conditions: Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita
Interventions: Erlotinib; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pachyonychia Congenita
Interventions: PTX-022, Placebo; Drug
Lead sponsor: Palvella Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 6 more

Conditions: Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more

Conditions: Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee Pain
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: Benedict Alter; Other
Eligibility: 45 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: GBT021601; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Healthy
Interventions: Lansoprazole, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

AngioDefender Versus Brachial Artery Ultrasound Imaging

Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)

Impact of Standing Programs in Children With Spina Bifida: A Single Subject Design

MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

A Study of LY3337641 in Rheumatoid Arthritis

Safety Study of Atomoxetine and Cerebrovascular Outcomes

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects